TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12706934
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/day for four weeks)
Study: 12706934
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day for four weeks)
Study: 10921161
Drug: Yi Zhi
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yi Zhi Capsules (YZC)
Study: 8769292
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG solution 250 ml twice a day
Study: 6141335
Drug: gamma-vinyl GABA
Normalized name: gamma-Vinyl GABA
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gamma-vinyl GABA (3 g daily)
Study: 22956656
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intradermal (i.d.) vaccination
Study: 22956656
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intramuscular (i.m.) vaccination
Study: 22956656
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intramuscular (i.m.) vaccination
Study: 20119464
Drug: tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: tapentadol IR (50, 75, or 100 mg every 4 or 6 hours, maximum TDD 500 mg)
Study: 20119464
Drug: tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tapentadol ER (100, 150, 200, or 250 mg bid)
Study: 16277587
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment before 28 weeks of gestation (N = 580)
Study: 16277587
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving periodontal treatment after delivery (N = 290)
Study: 16277587
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment (treatment group) vs. no treatment (control group)
Study: 16277587
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment (treatment group) vs. gingivitis risk
Study: 9627365
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg daily added to ERT
Study: 9627365
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) in nonsmoking women
Study: 9627365
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) in cigarette smokers
Study: 3287837
Drug: Clofibric acid
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofibric acid and nicotinic acid (Treatment group)
Study: 31166679
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen)
Study: 31166679
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen)
Study: 31166679
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus endocrine therapy (in subgroup of 495 patients who received an aromatase inhibitor)
Study: 28390934
Drug: Comparator quadrivalent
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator quadrivalent inactivated influenza vaccine (IIV4)
Study: 21245887
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no L. sporogenes supplementation)
Study: 16476114
Drug: Glyburide tablets
Normalized name: Glyburide Tablets
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide tablets
Study: 9058613
Drug: Local therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapies (intraocular injections of ganciclovir and foscarnet)
Study: 9058613
Drug: Sustained-release ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release ganciclovir implant
Study: 9058613
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of local and systemic therapies
Study: 8132367
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg on the first day, then 300 mg daily)
Study: 8132367
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.5 mg/kg body weight) + Flucytosine (3 x 2.5 g daily)
Study: 25891697
Drug: Tacrolimus modified
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus modified release (TAC-MR) once daily
Study: 25891697
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) twice daily
Study: 9817160
Drug: Nebulized L-NAME
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized L-NAME (10(-1) M)
Study: 825745
Drug: Trental 400
Normalized name: Trental 400mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trental 400 (1 tablet 3 times a day for 7 to 8 weeks)
Study: 15132131
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 100‐mg capsules (reference)
Study: 15132131
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 100‐mg tablets (test)
Study: 15132131
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 400‐mg tablet (test)
Study: 15132131
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 100‐mg tablets versus 4 x 100‐mg capsules
Study: 15132131
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 400‐mg tablet versus 4 x 100‐mg capsules
Study: 12034517
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol sequentially combined with dydrogesterone (oE2/D10)
Study: 12034517
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol plus norethisterone acetate (tdE/NETA)
Study: 7853047
Drug: Streptokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase treatment for acute myocardial infarction
Study: 30860570
Drug: Capivasertib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib (400 mg b.i.d. 4 days on/3 days off) with paclitaxel (90 mg/m2 on days 1, 8, and 15 of a 28-day cycle)
Study: 30860570
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with paclitaxel (90 mg/m2 on days 1, 8, and 15 of a 28-day cycle)
Study: 26336043
Drug: Adaptive Compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Compression Therapy (ACT)
Study: 23252914
Drug: Discharge-planning intervention
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discharge-planning intervention combining chronic drug review, education, and enhanced transition-of-care communication
Study: 19635148
Drug: Percutaneous transluminal
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous transluminal renal artery stenting (PTRAS) plus best medical treatment
Study: 16636345
Drug: Exercises (pendular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercises (pendular swinging and stretching exercises 5 minutes twice a day every day)
Study: 12468560
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 50 mg daily
Study: 9438743
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug run-in period
Study: 851303
Drug: High-glucose-concentration dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose-concentration dialysate (717 mg/dl)
Study: 851303
Drug: Intravenous mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mannitol (1g/kg)
Study: 851303
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-glucose-concentration dialysate and intravenous mannitol
Study: 851303
Drug: High-glucose-concentration dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose-concentration dialysate and intravenous mannitol
Study: 29945920
Drug: Iberdomide (0.03-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.03-6 mg, n=6 across seven cohorts)
Study: 29945920
Drug: Iberdomide (0.03-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.03-6 mg)
Study: 29945920
Drug: Iberdomide (0.3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.3-6 mg)
Study: 22360996
Drug: Frequent hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent hemodialysis (6 times per week daily in-center hemodialysis)
Study: 18063446
Drug: Virosomal subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal subunit influenza vaccine (vSIV, brand: Invivac)
Study: 18063446
Drug: MF59-adjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted subunit influenza vaccine (adSIV, brand: Fluad)
Study: 18063446
Drug: Conventional subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subunit influenza vaccine (SIV, brand: Influvac)
Study: 18063446
Drug: Virosomal subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal subunit influenza vaccine (vSIV)
Study: 10527227
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (10 microg/kg)
Study: 8669361
Drug: Conscious sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conscious sedation by means of intravenous midazolam (0.1 mg/kg)
Study: 2045854
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy for 12 courses
Study: 2045854
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy for 8 courses followed by Adriamycin for 4 courses
Study: 25733743
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy (n = 100)
Study: 17133582
Drug: Pramipexole (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (median dose 0.35 mg/day)
Study: 17133582
Drug: Placebo (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (median dose 0.47 mg/day)
Study: 15878754
Drug: VEGF gene
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF gene polymorphism (BstUI C/T) in patients with oral cancer
Study: 15878754
Drug: T/C ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/C ratio in patients with oral cancer
Study: 1282616
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg, twice daily for 21 days)
Study: 25694481
Drug: ANG II
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANG II infusion
Study: 19940229
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of golimumab 100 mg (30‐minute infusion, n = 23)
Study: 19940229
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of golimumab 100 mg at upper arm (n = 18)
Study: 19940229
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of golimumab 100 mg at abdomen (n = 18)
Study: 19940229
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of golimumab 100 mg at thigh (n = 19)
Study: 19940229
Drug: Overall SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall SC administration of golimumab 100 mg
Study: 19940229
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of golimumab 100 mg
Study: 19940229
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of golimumab 100 mg
Study: 18379535
Drug: Glucose solutions
Normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solutions
Study: 16802519
Drug: Beta-blockers, ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers, ACE inhibitors/AT1 receptor antagonists, diuretics, aldosterone antagonists, and glycosides (specific dosages and durations not available)
Study: 14581346
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg rofecoxib once a day for 9 months
Study: 14581346
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg rofecoxib once a day
Study: 10947698
Drug: Caudal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine 0.2% 1 ml/kg
Study: 10947698
Drug: Caudal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine 0.2% 1 ml/kg plus caudal ketamine 0.25 mg/kg
Study: 9224783
Drug: [14C]avitriptan 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: [14C]avitriptan 20 mg/kg iv and oral in rats; 10 mg iv and 50 mg oral in humans
Study: 30124733
Drug: Nature-based regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nature-based regimen (NR) containing natural oils, beeswax, and witch hazel, and day & night creams containing natural oils, glycerin, and botanical anti-inflammatories
Study: 30124733
Drug: Synthetic dermatologist-recommended
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic dermatologist-recommended regimen (CR) containing cetyl alcohol, sodium lauryl sulphate-containing cleanser and glycerin, polyisobutene-containing lotion
Study: 20819314
Drug: Subcutaneous IFN-gamma
Normalized name: IFN-gamma 1b
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFN-gamma injection
Study: 3138441
Drug: BCAA-enriched amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-enriched amino acid solution
Study: 27768643
Drug: Transcanalicular laser‐assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcanalicular laser‐assisted dacryocystorhinostomy with endonasal augmentation without intubation
Study: 27768643
Drug: Transcanalicular laser‐assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcanalicular laser‐assisted dacryocystorhinostomy with endonasal augmentation with bicanalicular intubation
Study: 22311378
Drug: Kava (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava (180 mg of kavalactones)
Study: 19452698
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride tablets for 24 weeks
Study: 11726450
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine plus 0.5 microg/mL sufentanil (BS group)
Study: 11726450
Drug: 0.125% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% ropivacaine plus 0.5 microg/mL sufentanil (RS group)
Study: 8478307
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg once daily for 7 days
Study: 8478307
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg four times daily for 7 days
Study: 8478307
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg once daily for 7 days (European study)
Study: 8478307
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg once daily for 7 days (Italian study)
Study: 8478307
Drug: Miocamycin 600
Normalized name: miocamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miocamycin 600 mg twice daily for 7 days (Italian study)
Study: 28520754
Drug: IWT +
Normalized name: Ibuprofen and Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IWT + high-dose post-exercise milk product intake (HD, n = 13)
Study: 28520754
Drug: IWT +
Normalized name: Ibuprofen and Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IWT + low-dose post-exercise milk product intake (LD, n = 12)
Study: 26171983
Drug: Intranasal 8
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 8 IU OT
Study: 26171983
Drug: Intranasal 24
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 24 IU OT
Study: 26171983
Drug: Intravenous 1
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1 IU OT
Study: 19566638
Drug: Support program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support program for stress management (homework for 3 months, nurse feedback monthly)
Study: 17513626
Drug: Caudal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caudal clonidine (2 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Study: 17513626
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine (50 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Study: 17513626
Drug: Caudal hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal hydromorphone (10 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Study: 15593020
Drug: Methylprednisolone with
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone with chlorambucil or cyclophosphamide (6-month treatment alternating every other month)
Study: 15593020
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting ACTH preparation (1 year treatment)
Study: 9931685
Drug: Intravenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glutamine substitution
Study: 11035984
Drug: Progesterone and
Normalized name: progesterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone and progestins; specific dosage and duration not mentioned.
Study: 11035984
Drug: Estrogen; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen; specific dosage and duration not mentioned.
Study: 8933313
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g daily with 1 g probenecid)
Study: 8933313
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g daily with 1 g probenecid)
Study: 29134744
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium propionate (6845 mg)
Study: 29134744
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (4164 mg)
Study: 22767424
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment preference
Study: 22767424
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only preference
Study: 22767424
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment preference
Study: 20039429
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil (target dosage 3 gm/day)
Study: 20039429
Drug: intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous cyclophosphamide (0.5‐1.0 gm/m(2)/month)
Study: 15333078
Drug: Oral d,l‐sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d,l‐sotalol (196 +/- 42 mg/day for 7 days)
Study: 15333078
Drug: Oral d,l‐sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d,l‐sotalol (216 +/- 51 mg/day)
Study: 11605744
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) in adherent PBMC group (n = 20)
Study: 11605744
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) in total PBMC group (n = 9)
Study: 8085482
Drug: Structured Learning
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Learning Therapy (SLT)
Study: 2665639
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (23 mg of elemental zinc lozenges taken every 2 hours)
Study: 2665639
Drug: Placebo (taste-matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (taste-matched sucrose octaacetate lozenges)
Study: 25923550
Drug: Rociletinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rociletinib (500 mg to 1000 mg twice daily)
Study: 23889096
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of benazepril (0.45 mg/kg daily for 4 days)